Sygnature Discovery, a drug discovery contract research organization (CRO), announced Susanne Back as its new Head of In Vivo Pharmacology. The company has recently launched a strategic rebrand reflecting its two-plus decades of growth, investment, and targeted acquisitions.

Makeup of Sygnature In Vivo Team

Back will oversee approximately 30 scientists, working with both clients and multidisciplinary project teams to deliver robust in-vivo strategies. Her responsibilities include scientific and operational leadership in the forms of resource planning, workflow optimization, and the like.

Sygnature predicts this will result in more informed decision-making across its drug discovery programs. With the move, the company strengthens its bioscience leadership, reinforcing its commitment to delivering high-quality, integrated solutions.

Back will also give expert input into study design in her role as a scientific and operational point of contact. She said Sygnature’s co-located, multidisciplinary teams, supported by AI and automation, signify the caliber of its scientific community.

“I was particularly attracted to Sygnature because of its world-leading integrated drug discovery expertise,” Back said. “The co-located, multidisciplinary environment creates a truly collaborative setting where complex discovery challenges can be addressed efficiently.”

Fraser McIntosh, who serves as Sygnature’s Vice President of In Vivo Pharmacology, also weighed in on the new hire.

“Susanne brings deep scientific expertise in in-vivo pharmacology alongside a strong track record of leading high-performing teams,” McIntosh said.

Previous Experience in In Vivo Pharmacology

Among those, Back has held scientific and leadership roles at Orion Pharma and Charles River.

“[Back’s] ability to translate project objectives into well-designed in-vivo strategies will be instrumental in strengthening our integrated offering,” McIntosh said.

McIntosh added the appointment will continue to ensure high-quality, decision-enabling data for Sygnature’s customers.

Back’s team will work out of Sygnature’s headquarters in Nottingham, UK.